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Glucagon is a 29–amino acid pancreatic hor-
mone that is secreted from the pancreatic
α-cells into the portal blood supply in response
to hypoglycemia, acting as the counter-regula-
tory hormone to insulin. Its main biologic
effect is the regulation of glucose metabolism
by enhancing the synthesis and mobilization of
glucose in the liver. There is solid evidence
demonstrating that the inhibition of glucagon
signaling in vivo leads to a reduction of plasma
glucose (Jiang and Zhang 2003). In addition,
glucagon has many extrahepatic effects, such as
the increase of lipolysis in adipose tissue, a pos-
itive inotropic effect in the heart, a role in the
satiety control in the central nervous system,
and the regulation of the glomerular ﬁltration
rate (Berne and Levy 1993). In the islets of
Langerhans, it participates in the regulation of
intraislet hormone, insulin, somatostatin, and
glucagon secretion (Gromada et al. 1997a; Ma
et al. 2005). When insulin secretion from
β-cells is impaired, diabetes mellitus develops.
In this pathology, the normal physiologic sup-
pression of glucagon secretion from pancreatic
α-cells in response to elevated plasma glucose
is lost (Unger and Orci 1981a, 1981b). A con-
comitant decrease in early insulin secretion in
response to oral glucose is also observed. These
combined defects alter the insulin-to-glucagon
ratio, leading to a failure of the normal sup-
pression of endogenous glucose production
that occurs after ingestion of oral glucose
(Gerich 1997). This contributes to the eleva-
tion of glucose levels in plasma in individuals
with impaired glucose tolerance or diabetes.
Despite the great importance of α-cells,
little is known about the stimulus secretion
coupling and its regulation by other hormones
and neurotransmitters. This is partly due to
the scarcity of islet tissue and small proportion
of α-cells compared with insulin-releasing
β-cells. α-Cells contain a specific set of ion
channels, including a voltage-dependent Na+
channel, responsible for their electrical activity
(Göpel et al. 2000; Rorsman and Hellman
1988; Salehi et al. 1996). Consequently, the
intracellular calcium ion [Ca2+]i oscillates at
low glucose concentrations (Berts et al. 1996;
Nadal et al. 1999). Because of the calcium
influx, the exocytotic machinery is initiated
and glucagon is released (Göpel et al. 2004;
Gromada et al. 1997b). When the extracellular
glucose concentration increases to the level
needed for insulin to be released, the frequency
of [Ca2+]i oscillations diminishes and, as a con-
sequence, glucagon release decreases (Nadal
et al. 1999; Opara et al. 1988).
Although the endocrine pancreas is not
considered a classic estrogen target, estrogen
effects on insulin and glucagon secretion and
receptors of a classical and nonclassical nature
are present in islet cells (Nadal et al. 2004;
Sutter-Dub 2002). [Ca2+]i oscillations have
recently been described as ﬁnely regulated by
17β-estradiol (17β-E2) in both α- and β-cells.
In the glucagon-containing α-cells, 17β-E2
provokes the suppression of [Ca2+]i oscilla-
tions generated by low glucose, whereas in
β-cells the gonadal hormone potentiates Ca2+
signals (Ropero et al. 2002). In both types of
cells the 17β-E2 effect is initiated after bind-
ing to a nonclassical membrane estrogen
receptor (ncmER) (Nadal et al. 2000; Ropero
et al. 2002).
Environmental estrogens are endocrine-
disrupting chemicals (EDCs) that in many
cases imitate the actions of the natural hor-
mone 17β-E2, eliciting deleterious effects on
humans and wildlife (Colborn et al. 1996;
Guillette et al. 1996; Hayes et al. 2002; Hunt
et al. 2003). It is well accepted that EDCs
exert their effects after binding at the classical
ER-α and ER-β, inducing classic nuclear
actions (Grünfeld and Bonefeld-Jorgensen
2004; McLachlan 2001). Most of the effects
described through the classical pathway occur
at micromolar concentrations of EDCs.
Evidence accumulated in the last few years
indicates that EDCs imitate 17β-E2 actions
through alternative pathways, which in some
cases are unrelated to classical ERs (McLachlan
2001; Nadal et al. 2005; Witorsch 2002).
Some of these pathways are activated at pico-
molar and nanomolar concentrations of EDCs
(Bulayeva and Watson 2004; Nadal et al.
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Glucagon, secreted from pancreatic α-cells integrated within the islets of Langerhans, is involved in
the regulation of glucose metabolism by enhancing the synthesis and mobilization of glucose in the
liver. In addition, it has other extrahepatic effects ranging from lipolysis in adipose tissue to the
control of satiety in the central nervous system. In this article, we show that the endocrine disrup-
tors bisphenol A (BPA) and diethylstilbestrol (DES), at a concentration of 10–9 M, suppressed low-
glucose–induced intracellular calcium ion ([Ca2+]i) oscillations in α-cells, the signal that triggers
glucagon secretion. This action has a rapid onset, and it is reproduced by the impermeable mole-
cule estradiol (E2) conjugated to horseradish peroxidase (E-HRP). Competition studies using
E-HRP binding in immunocytochemically identiﬁed α-cells indicate that 17β-E2, BPA, and DES
share a common membrane-binding site whose pharmacologic proﬁle differs from the classical ER.
The effects triggered by BPA, DES, and E2 are blocked by the Gαi- and Gαo-protein inhibitor per-
tussis toxin, by the guanylate cyclase–specific inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-
1-one, and by the nitric oxide synthase inhibitor N-nitro-L-arginine methyl ester. The effects are
reproduced by 8-bromo-guanosine 3',5'-cyclic monophosphate and suppressed in the presence of
the cGMP-dependent protein kinase inhibitor KT-5823. The action of E2, BPA, and DES in pan-
creatic α-cells may explain some of the effects elicited by endocrine disruptors in the metabolism of
glucose and lipid. Key words: cGMP, endocrine disruptors, environmental estrogens, estrogen
receptors, glucagon, islets of Langerhans, nongenomic, second messengers. Environ Health Perspect
113:969–977 (2005). doi:10.1289/ehp.8002 available via http://dx.doi.org/ [Online 18 May 2005]
Research2000; Quesada et al. 2002; Wozniak et al.
2005).
We have described in pancreatic β-cells
the effect of two EDCs: bisphenol A (BPA),
found in polycarbonate plastic, in the content
of food in coated cans, dental sealant, and
composites (Brotons et al. 1995; Sonnenschein
and Soto 1998), and diethylstilbestrol (DES), a
synthetic estrogen used between the 1940s and
the 1970s to prevent miscarriages (Newbold
2004). Both bind to an ncmER to induce
[Ca2+]i signals at concentrations as low as
10–9 M (Nadal et al. 2000). In addition,
10–9 M BPA via the ncmER activates the tran-
scription factor CREB (Quesada et al. 2002).
In pancreatic β-cells, we used laser scan-
ning confocal microscopy to study [Ca2+]i
movements as an index of changes in intra-
cellular signaling because [Ca2+]i signals are
involved in a large number of signaling
processes, from secretion to gene expression
(Quesada and Soria 2004; Soria et al. 2004).
We used pancreatic α-cells within freshly iso-
lated islets of Langerhans, the physiologic
unit of the endocrine pancreas. This prepara-
tion is similar to the actual physiologic situa-
tion as demonstrated by [Ca2+]i and electrical
activity recordings in vivo (Fernandez and
Valdeolmillos 2000; Sanchez-Andres et al.
1995). Moreover, this methodology excels
when applied to this particular type of cell,
which is very difﬁcult to work with because of
its scarcity (α-cells represent only about
10–20% of the total number of islet cells, i.e.,
~ 150–300 cells per islet). Using this approach,
we demonstrated that low doses of BPA and
DES imitate the E2-induced blockade of Ca2+
signals in glucagon-releasing α-cells within
intact islets of Langerhans. This effect is
mediated by the interaction with an ncmER
and involves G-proteins, nitric oxide synthase
(NOS), and cGMP-dependent protein kinase
(PKG).
Materials and Methods
Materials. We obtained Fluo-3 AM from
Molecular Probes Inc. (Leiden, the Nether-
lands); ICI182,780 and 1H-[1,2,4]oxadia-
zolo[4,3-a]quinoxalin-1-one (ODQ) from
Tocris Cookson Ltd. (Avonmouth, UK); and
KT-5823 from Alomone Labs (Jerusalem,
Israel). Other chemicals were obtained from
Sigma (Madrid, Spain). We also obtained
estradiol–horseradish peroxidase (E-HRP)
from Sigma; however, it is not available from
this company at the present time.
Measuring intracellular calcium in α-cells
within intact islets of Langerhans. Swiss
albino OF1 male mice (8–10 weeks of age)
were killed by cervical dislocation according
to national guidelines provided by our animal
house. An internal animal care and use com-
mittee reviewed and approved the method
used. 
Pancreatic islets of Langerhans were iso-
lated by collagenase digestion as previously
described (Nadal et al. 1998) and loaded with
5 µM Fluo-3 AM for at least 1 hr at room
temperature. Loaded islets were kept in a
medium containing 115 mM NaCl, 10 mM
NaHCO3, 5 mM KCl, 1.1 mM MgCl2,
1.2 mM NaH2PO4, 2.5 mM CaCl2, and
25 mM HEPES, plus 1% albumin and 5 mM
D-glucose, continuously gassed with a mixture
of 95% O2 and 5% CO2 (pH 7.35). Islets
were perfused at a rate of 1 mL/min with a
modiﬁed Ringer solution containing 120 mM
NaCl, 5 mM KCl, 25 mM NaHCO3,
1.1 mM MgCl2, and 2.5 mM CaCl2 (pH 7.35
when gassed with 95% O2 and 5% CO2). It
took 30–60 sec to change the bath volume
completely; this may explain the different
response times for some of the experiments.
Calcium records in individual cells were
obtained by imaging intracellular calcium
under a Zeiss PASCAL5 confocal microscope
using a Zeiss 40× oil-immersion lens, with
numerical aperture 1.3 (Zeiss, Jena, Germany).
Images were collected at 2-sec intervals, and
the time course of fluorescent signals from
individual cells were measured using the Zeiss
LSM software package (Zeiss, Heidelberg,
Germany). Experiments were performed at
34°C. Results were plotted using commercially
available software (Sigmaplot; Jandel Scientiﬁc,
Erkrath, Germany) in which the change in ﬂu-
orescence (∆F) is expressed as a percentage of
the basal fluorescence (F0) observed in the
absence of stimulus or during the intervals
between spikes. α-Cells within the islets were
identiﬁed by their [Ca2+]i oscillatory pattern in
0.5 mM glucose (Nadal et al. 1999; Quesada
et al. 1999). The frequency of [Ca2+]i oscilla-
tions was calculated during a period of
2–4 min before stimuli application (control),
and the frequency was measured during 5 min
of stimuli application calculated over the
period from minute 5 to minute 10 after stim-
uli were applied. Because a stable baseline
before stimuli application was nonexistent, a
spike was deﬁned by a rapid increase in [Ca2+]i
higher than twice the SD of background sig-
nals at the intervals between spikes. Spikes
were counted manually.
Cell isolation and culture. Isolated islets
were dispersed into single cells and cultured as
previously described (Nadal et al. 1998).
Brieﬂy, islets were disaggregated into single cells
with trypsin. Cells were then centrifuged, resus-
pended in RPMI 1640 culture medium supple-
mented with 10% fetal calf serum, 200 U/mL
penicillin, 0.2 mg/mL streptomycin, 2 mM
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Figure 1. Fluorescence changes monitored from individual cells within intact islets of Langerhans.
(A) Transmission image of an intact islet of Langerhans. (B) Color image of the same islet of Langerhans
shown in A loaded with the calcium-sensitive dye Fluo-3 and exposed to 0.5 mM glucose; bar = 20 µm
(color scale: blue, low calcium; red, high calcium). (C) Islets exposed to 0.5 mM glucose were switched to
11 mM glucose, as indicated by the bars above the trace. Note that the low-glucose oscillatory pattern is
suppressed in the presence of a high glucose concentration (11 mM). 
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0L-glutamine, and 11 mM glucose and plated
on poly-L-lysine–coated glass coverslips. Cells
were kept at 37°C in a humidiﬁed atmosphere
of 95% O2 and 5% CO2 for 24 hr.
Estradiol-HRP binding assay. The E-HRP
binding assay was performed as previously
described (Nadal et al. 2000; Ropero et al.
2002). Brieﬂy, after 24 hr in culture, cells were
gently fixed to avoid permeabilization and
exposed overnight to 4.5 µg/mL E-HRP plus
the testing reagent at 4°C. This was the appro-
priate concentration of E-HRP to obtain a suit-
able labeling of the cell membrane. E-HRP
binding was visualized by the precipitate
formed when reacting with 3,3´-diaminobenzi-
dine tetrahydrochloride (DAB) in the presence
of urea hydrogen peroxide and CoCl2 for
15 min [SIGMA FAST DAB with metal
enhancer tablet set (Co-DAB)]. The light
absorbed by the precipitate was measured; the
lower the percentage of absorbed light, the
higher the competition for an E-HRP binding
site. The quantity of E-HRP bound is expressed
as the percentage of absorbed light compared
with the control condition. In order to obtain
an appropriate staining background, incubation
and developmental procedures with peroxidase
were performed in identical conditions. All of
the chemicals tested for competition with E-
HRP were used in a concentration 300-fold
higher than that of E-HRP.
Immunocytochemistry. α-Cells were identi-
fied using antiglucagon antibody labeling.
After staining with E-HRP and Co-DAB, the
cells were permeabilized with 1% Triton
X-100 for 2 min, and immunocytochemistry
was performed as previously described (Ropero
et al. 2002).
Results
Effect of EDCs and E2 on low-glucose–
induced [Ca2+]i oscillations. To investigate the
effect of E2 and EDCs in pancreatic α-cells,
[Ca2+]i recordings were obtained from intact
islets of Langerhans (Figure 1A) loaded with
the fluorescent calcium-sensitive dye Fluo-3
and imaged using laser scanning confocal
microscopy (Figure 1B). Although only the
periphery of the islet is loaded, as previously
described (Nadal et al. 1999; Ropero et al.
2002), all the different types of cells within the
islet are represented and can be easily identiﬁed
by their [Ca2+]i response to glucose (Nadal
et al. 1999; Quesada et al. 1999). Pancreatic
α-cells are distinguished by their particular
oscillatory [Ca2+]i pattern in the absence of
glucose, which diminishes as the glucose con-
centration is increased (Figure 1C).
Typical α-cells presented a [Ca2+]i oscil-
latory pattern in the absence of glucose,
which was completely suppressed by 1 nM
BPA in almost 50% (20 of 41) of the cells
(Figure 2A,D) and by 1 nM DES in 31% of
the cells (14 of 45 cells; Figure 2B,D). In all
the remaining cells, both EDCs largely
reduced the frequency of [Ca2+]i oscillations
(Figure 2E). To calculate the average effect on
the frequency of [Ca2+]i (Figure 2E), an aver-
age of all cells was performed. The pesticide
1,1,1-trichloro-2-[o-chlorophenyl]-2,2[p-
chlorophenyl]ethane (o,p´-DDT), was less
active, producing a complete blockade in only
7% (3 of 41) of the cells tested (Figure 2C,D).
The onset of the effect of BPA and DES was
very rapid, and the decrease of the frequency
of [Ca2+]i oscillations was similar to the one
obtained with E2 and the membrane-imper-
meable E-HRP (Figure 2E,F). We used a con-
centration of E-HRP that was equivalent to
the molecules of E2. Because the effect was
present at a concentration equivalent to 1 nM
E2, the effect should be produced by the con-
jugated form; if free 17β-E2 was present, it
would be in a much lower concentration. The
effect of o,p´-DDT was significantly smaller
than that of the other estrogenic compounds
(Figure 2E,F). E2 and EDC effects were irre-
versible after 20 min in a solution of 0.5 mM
glucose, as previously described for E2 (Ropero
et al. 2002). The speediness of the action and
the fact that E-HRP mimics the actions of E2,
BPA, and DES indicate that these EDCs act
through an E2 binding site, probably located
at the plasma membrane.
A common membrane-binding site is
shared by E2, BPA, and DES. To further
demonstrate the implication of a membrane
binding site, we used a binding assay method
based on the interaction of E-HRP as a speciﬁc
probe to detect E2 binding sites at the plasma
membrane of nonpermeabilized cells. E-HRP
bound to the plasma membrane is developed
using DAB; the DAB-based primary reaction
Xenoestrogen regulation of [Ca2+]i via PKG in pancreatic α-cells
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Figure 2. Effect of EDCs on [Ca2+]i in pancreatic α-cells within the islets of Langerhans in response to 1 nM
BPA (A), 1 nM DES (B), and 1 nM o,p´-DDT (C) , in the presence of 0.5 mM glucose. (D) Percentage of cells
with a complete blockade of [Ca2+]i oscillations 5 min after application of stimuli. (E) Effect on the fre-
quency of [Ca2+]i oscillations after the stimuli were applied for 5 min and calculated over a 5–10 min
period. G1–G5 are the frequencies of [Ca2+]i in the presence of 0.5 mM glucose measured during a 2–4 min
interval before stimuli application, and E2, HRP, BPA, EDS, and DDT represent the frequency values after
5 min application of the compound (see “Materials and Methods” for details). (F) Frequency (%) of [Ca2+]i
after stimuli compared with control conditions. Note that the decrease in the frequency is 80% in the pres-
ence of 1 nM BPA. Error bars in E and F indicate SE. 
*p < 0.01, **p < 0.0001, Student t-test, comparing each stimulus with its own control.
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E2 E-HRP BPA DES DDTproduct of peroxidase was used as an indica-
tion of the amount of E-HRP bound to the
estrogen-binding sites. This primary reaction
product is highly absorptive of laser light at
543 nm and can be easily visualized with high
contrast by using transmission laser scanning
microscopy (Nadal et al. 2000). This assay has
been combined with immunocytochemistry
against glucagon performed afterward to study
speciﬁcally the characteristics of the E2 binding
site in glucagon-containing α-cells (Ropero
et al. 2002). Figure 3A shows several E-HRP
control cells after being developed with
Co-DAB; two of them were identified as
glucagon-containing α-cells by immuno-
staining (Figure 3D). These control cells pre-
sented a black staining that absorbed the light
of 543 nM from the laser beam (Figure 3G).
When DES was added at the same time as
E-HRP, it decreased the binding of E-HRP
to its binding site at the plasma membrane,
producing a reduced amount of precipitate.
This can be easily visualized by a lower light
absorption (Figure 3B,E), and it has been
quantiﬁed in Figure 3G. Figure 3C shows the
basal level when α-cells are incubated only
with HRP. This background level has been
subtracted in all experiments.
Figure 3G shows that BPA, DES, and E2
bind to the same membrane-binding site.
Remarkably, the pesticide o,p´-DDT, which
was weaker in inducing the abolishment of
[Ca2+]i signals, presented a very low competi-
tion. This may indicate that the EDCs con-
taining phenol groups, that is, DES and BPA,
mimic the effects of 17β-E2, which also con-
tains a phenolic A-ring in its structure, by
binding at the same membrane-binding site.
However, o,p´-DDT, which contains no
hydroxylated moieties in its structure, was less
potent.
To characterize whether the membrane-
binding site is an ncmER, we tested whether
actions of BPA, DES, and E2 were modiﬁed
by the pure antiestrogen ICI182,780, which
inhibits ER-mediated effects. Figure 4 shows
that the effects of BPA and DES were not
modiﬁed by ICI182,780. In fact, BPA com-
pletely suppressed [Ca2+]i oscillations in all the
cells tested (n = 8, four islets), and DES
blocked low-glucose–induced [Ca2+]i oscilla-
tions in 10 of 13 cells (ﬁve islets), and in the
remaining three cells it largely reduced the fre-
quency of [Ca2+]i oscillations (Figure 4C).
ICI182,780 did not modify the frequency of
low-glucose–induced [Ca2+]i oscillations
(Figure 4C): ICI182,780 controls ICI1–ICI3
range from 0.8/min to 1.4/min, well within
the range described for 0.5 mM glucose
(Figure 2E). This, along with the experiment
described in Figures 2 and 3, strongly suggests
that EDC effects are mediated by a membrane
ER with a different pharmacologic profile
than that of the classical ERs.
cGMP and PKG mediate rapid effects of
BPA and E2. The experiments described to
this point suggested that the actions of BPA
and DES are mediated through the same
receptor as is 17β-E2 in α-cells. For that rea-
son, we used BPA as the paradigmatic EDC in
this system to further analyze the molecular
pathway involved. Because we have previously
described that cGMP and PKG were impli-
cated in the case of the natural hormone
(Ropero et al. 2002), we sought to study their
effects on the action of BPA. Application of
10 µM 8-bromo-guanosine 3´,5´-cyclic
monophosphate (8Br-cGMP) mimicked the
effects of BPA, DES, and E2 on [Ca2+]i oscilla-
tions (Figure 5A), as previously demonstrated
(Ropero et al. 2002; Sugino et al. 2002).
Given that the action of cGMP was probably
mediated by PKG, we tested the action of
8Br-cGMP in cells pretreated with the mem-
brane-permeable PKG inhibitor KT-5823 for
1 hr. Pretreatment with the PKG inhibitor did
not have any effect on low-glucose–induced
[Ca2+]i oscillations (Figure 5C), but it almost
completely blocked 8Br-cGMP action
(Figure 5B,C).
When we used KT-5823 pretreated islets
to test the effect of BPA, we found that the
PKG inhibitor completely blocked BPA
action (Figure 6A,B). Thus, KT-5823 does
not alter [Ca2+]i oscillations but prevents the
suppression of low-glucose–induced [Ca2+]i
oscillations by BPA, indicating that BPA’s
effect is exerted by a cGMP/PKG-mediated
mechanism, as has been demonstrated for the
natural hormone 17β-E2 (Figure 6C).
Involvement of soluble guanylate cyclase
and NOS in BPA and E2 actions. In many cell
types, increases in cGMP levels are due to the
Alonso-Magdalena et al.
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Figure 3. Binding assays with E-HRP and HRP and competition with E2, BPA, DES, and DDT. (A–C)
Transmission images of nonpermeabilized pancreatic cells with E-HRP or HRP developed using Co-DAB:
(A) cells incubated with E-HRP as control, (B) competition of 30 µM DES for the binding site of E-HRP, and
(C) background staining with 100 nM HRP. (D–F) Glucagon-secreting cells identiﬁed by immunocytochem-
istry: (D) identiﬁcation of the α-cells present in (A), (E) the same α-cell as in (B), and (F) the same cell as in
(C) stained with antiglucagon antibody. (G) Competition for E-HRP binding site at the plasma membrane by
30 µM E2, BPA, DES, and DDT. Background binding obtained with 100 nM HRP has been subtracted. Data
are from three duplicate experiments, expressed as mean + SE. Bars = 5 µm. 
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Figure 4. Effects of the pure antiestrogen ICI182,780 (1 µM) on 1 nM BPA (A) and 1 nM DES (B) action on low-glucose–induced [Ca2+]i oscillations. ICI182,780 was
perfused for at least 20 min before stimuli were added, and it was maintained during the whole period. (C) Mean frequencies in [Ca2+]i oscillations in the presence
of ICI182,780 (ICI) for each experiment (ICI1–ICI3) and in the presence of each stimulus. Results are representative of at least eight cells from four different islets,
expressed as mean ± SE. 
*p <1 0 –5, Student t-test comparing each stimulus with its own control.
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B Aactivation of soluble guanylate cyclase (GC)
after NO generation by NOS. To test if this
pathway was responsible for the BPA and E2
actions described above, we started by testing
the effect of the NO donor sodium nitroprus-
side (SNP). In cells that oscillate as usual in the
presence of 0.5 mM glucose, SNP abolishes
these [Ca2+]i oscillations (Figure 7A,C). This
effect resembles those produced by 8Br-cGMP
and the estrogenic compounds BPA and E2.
To check whether the NO effects on [Ca2+]i
oscillations were mediated by an increase in the
intracellular levels of cGMP, we applied SNP
after blocking GC activity with the selective
inhibitor ODQ (Garthwaite et al. 1995). As
shown in Figure 7, B and C, ODQ did not
modify the average oscillatory frequency of
[Ca2+]i but completely blocked SNP action.
Thus, blockade of GC activity prevented the
inhibitory effect of SNP, suggesting that the
action of NO is probably mediated by an
increase in the intracellular levels of cGMP.
To prove that the cGMP/PKG-mediated
actions of BPA and E2 described in Figure 6
involved the upstream activation of a GC, we
tested the effects of these compounds in
ODQ-treated islets. In Figure 8, we demon-
strate that the BPA and E2 inhibitions of low-
glucose–induced [Ca2+]i oscillations are
completely suppressed in the presence of
ODQ. Therefore, we have demonstrated that
BPA and E2 actions involve the activation of a
GC, probably by NO that generates cGMP,
which in turns activates PKG.
To assess whether NOS is responsible for
the generation of NO, we used the specific
antagonist N-nitro-L-arginine methyl ester
(L-NAME), which is known to block NOS
activation in pancreatic islets (Akesson et al.
1999; Novelli et al. 2004; Salehi et al.
1996). As shown in Figure 9, L-NAME
completely reversed the effect of BPA and E2
(Figure 9A,C,E), demonstrating that NOS
activation and the concomitant NO increase
are involved in the rapid actions of EDCs
and E2 in pancreatic α-cells.
BPA and E2 effects involve a G-protein–
coupled receptor. To asses the role of G-pro-
teins in the actions of EDC and E2 on [Ca2+]i
signals in α-cells, we used pertussis toxin
(PTX), an inhibitor of Gαi and Gαo. After a
4 hr preincubation with 100 ng/mL PTX, no
inhibitory effect of BPA and E2 was observed
(Figure 10A). Figure 10B shows the effect of
Xenoestrogen regulation of [Ca2+]i via PKG in pancreatic α-cells
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Figure 5. Effects of 8Br-cGMP on EDCs and E2 via PKG. (A) Exposure to 10 µM 8Br-cGMP dramatically reduces the frequency of low-glucose–induced [Ca2+]i oscil-
lations. (B) After incubation with the specific PKG inhibitor KT-5823 (1 µM), 8Br-cGMP fails to evoke the marked reduction in [Ca2+]i oscillations shown in (A).
(C) Mean frequency values collected in the presence of 0.5 mM glucose (G), 8Br-cGMP plus 0.5 mM glucose (8Br-cGMP), KT-5823 (KT), and 8Br-cGMP plus KT-5823
(8Br-cGMP + KT).Results are representative of at least ﬁve cells in four different islets, expressed as mean ± SE.
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obtained from the same mouse and in the
same conditions but in the absence of PTX.
The results obtained from different experi-
ments are summarized in Figure 10E. These
results support the involvement of either a
Gαi- or Gαo-coupled membrane receptor in
the [Ca2+]i regulation by BPA and E2.
Discussion
The ﬁndings described in this article demon-
strate that the endocrine disruptors BPA and
DES imitate the circulating hormone 17β-E2
in suppressing low-glucose–induced [Ca2+]i
oscillations in pancreatic α-cells within intact
islets of Langerhans. This rapid effect is
observed in a preparation that is almost identi-
cal to the physiologic situation: intact islets of
Langerhans used directly after their isolation.
The [Ca2+]i oscillatory pattern in β-cells
observed in vivo (Fernandez and Valdeolmillos
2000; Sanchez-Andres et al. 1995) are identi-
cal to those described with the present method
(Nadal et al. 1999; Santos et al. 1991). We
assume by these experiments performed in
β-cells that both preparations behave in a sim-
ilar manner.
It has been demonstrated that an ncmER
is involved in the rapid nongenomic effects of
estrogens in pancreatic α- and β-cells within
intact islets of Langerhans (Nadal et al. 2000;
Ropero et al. 2002). This ncmER is pharmaco-
logically different from classical ERs because it
is insensitive to antiestrogens such as tamoxifen
and ICI182,780 (Nadal et al. 2004). Moreover,
in pancreatic β-cells, BPA and DES bind to
ncmER at doses similar to those of 17β-E2,
inducing the potentiation of [Ca2+]i oscilla-
tions (Nadal et al. 2000). In this article, we
have shown that a common binding site exists
for BPA, DES, and E2 in immunocytochemi-
cally identiﬁed α-cells. This binding site has a
different pharmacologic proﬁle than classical
ERs: it binds BPA, DES, and E2 at a similar
dose. Moreover, the action of these agents is
triggered by remarkably low concentrations,
10–9 M. However, BPA is considered a weaker
estrogen about 1,000- to 2,000-fold less potent
than 17β-E2 when interacting with classical
ERs located in the cell interior (Krishnan et al.
1993; Kuiper et al. 1997). This result, along
with the absence of effect of the pure anti-
estrogen ICI182,780, strongly indicates an
action via a receptor other than the classical
ER. In addition, the ncmER involved in the
regulation of [Ca2+]i by 17β-E2 in α-cells uses
a cGMP/PKG-mediated pathway, the same
one demonstrated here for BPA. Therefore, the
receptor involved is very likely to be the same
ncmER responsible for the 17β-E2 actions pre-
viously described in α- and β-cells (Nadal et al.
2000; Ropero et al. 2002).
In other types of cells E2 induced rapid
cGMP/PKG-mediated actions. Upstream of
cGMP/PKG, NOS is activated, producing
NO and activating a GC that in turn increases
cGMP levels (Chambliss and Shaul 2002;
Rosenfeld et al. 2000; Xia and Krukoff 2004).
In the present study, the suppression of low-
glucose–induced [Ca2+]i oscillations by E2 and
BPA was reproduced by the NO donor SNP.
This effect was completely blocked when the
GC inhibitor ODQ was used, which indicates
that NO is exerting its effect by activating a
GC. When the GC inhibitor was used, E2 and
BPA had no effect on low-glucose–induced
[Ca2+]i oscillations. Moreover, when the NOS
inhibitor L-NAME was applied, E2 and BPA
produced no effect on [Ca2+]i. This demon-
strates that the actions of E2 and BPA are
mediated by NOS activation, which produces
NO and activates a GC. This is responsible
for the increase in cGMP and the downstream
activation of PKG that will likely block ion
channels (Figure 11).
The results for the mechanism of action of
E2 and BPA discussed above reinforce the idea
that environmental estrogens imitate 17β-E2
actions not only through the classical pathway
but also via other alternative pathways that do
not necessarily involve classical ERs (Nadal
et al. 2005). Alternative effects are triggered by
classical and nonclassical ERs located in the
cytosol and the plasma membrane (Nadal
et al. 2001). Two main molecular pathways
implicated are Src/PI3-Kinase/Akt and
Src/Ras/ERKs, which subsequently may acti-
vate NOS, as well as other enzymes (Alexaki
et al. 2004; Cardona-Gómez et al. 2003;
Guerra et al. 2004; Migliaccio et al. 2002;
Viso-Leon et al. 2004). A number of studies
have shown that both classical ERs associated
with the plasma membrane and other unique
membrane ERs activate G-proteins, initiating
different signaling cascades that, in some cases,
include the activation of NOS (Doolan and
Harvey 2003; Qiu et al. 2003; Razandi et al.
1999; Wyckoff et al. 2001). In the present
Alonso-Magdalena et al.
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Figure 8. Effect of E2 and BPA involving a GC. (A) When 1 nM 17β-E2 is applied in the presence of 10 µM ODQ, the [Ca2+]i oscillatory pattern is not modiﬁed. (B) Control
experiment performed with an islet from the same preparation and maintained in the same conditions as in (A) but without ODQ. (C) Treatment with 10 µM ODQ pre-
vents the effect of 1 nM BPA. (D) Control experiment performed with an islet from the same preparation and maintained in the same conditions as in (C) but without
ODQ. (E) Mean frequency values for experiments as in (A): 0.5 mM glucose and 10 µM ODQ (ODQ1), 1 nM 17β-E2 in the presence of 10 µM ODQ (ODQ + E2); experi-
ments as in (B): 0.5 mM glucose (G1), 1 nM 17β-E2; experiments as in (C): 0.5 mM glucose and 10 µM ODQ (ODQ2), 1 nM BPA in the presence of ODQ (ODQ + BPA);
experiments as in (D): 0.5 mM glucose (G2), 1 nM BPA. Results are representative of at least six cells from ﬁve different islets, expressed as mean ± SE.
*p < 10–5, Student t-test comparing E2 with G1 and BPA with G2.
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Estudy, the suppression of low-glucose–induced
[Ca2+]i oscillations is blocked by the action of
PTX, an inhibitor of Gαi and Gαo, indicating
that a G-protein–coupled receptor (GPCR) is
involved. All known GPCRs have seven trans-
membrane–spanning domains, whose intracel-
lular domains propagate the signal from the
receptor to the G-protein. It is possible that
the ncmER found in the endocrine pancreas
may be a seven-transmembrane domain
GPCR, as is the case with the orphan receptor
GPR30, which behaves as an estrogen mem-
brane receptor in breast cancer cells (Thomas
et al. 2005), and the new progestin receptor
discovered in teleosts (Zhu et al. 2003).
Another possibility is that a receptor with a
different structure from GPCRs is coupled to
a classical GPCR that activates Gα, which has
been proposed for ER-α in endothelial cells
(Wyckoff et al. 2001).
There are no extensive studies of endocrine
disruptors acting through the same alternative
pathways as the natural hormone 17β-E2.
Nonetheless, evidence has accumulated in
Xenoestrogen regulation of [Ca2+]i via PKG in pancreatic α-cells
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Figure 9. The NOS blocker L-NAME inhibits E2 and BPA actions. (A) When 1 nM 17β-E2 is applied in the presence of 100 µM L-NAME, the [Ca2+]i oscillatory pattern
is not modiﬁed. (B) Control experiment performed with an islet from the same preparation and maintained in the same conditions as in (A) but without L-NAME.
(C) Treatment with 100 µM L-NAME prevents the effect of 1 nM BPA. (D) Control experiment performed with an islet from the same preparation and maintained in
the same conditions as in (C) but without L-NAME. (E) Mean frequency values for experiments as in (A): 0.5 mM glucose and 100 µM L-NAME (L-NAME1), 1 nM
17β-E2 in the presence of 100 µM L-NAME (E2 + NAME); experiments as in (B): 0.5 mM glucose (G1), 1 nM 17β-E2; experiments as in (C): 0.5 mM glucose and
100 µM L-NAME (L-NAME2), 1 nM BPA in the presence of L-NAME (BPA + NAME); experiments as in (D): 0.5 mM glucose (G2), 1 nM BPA. Results are representa-
tive of at least 10 cells from eight different islets, expressed as mean ± SE. 
*p < 10–5, Student t-test comparing E2 with G1 and BPA with G2.
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Erecent years in this direction (Nadal et al.
2005). The activation of ERKs (extracellular
signal-regulated kinases) by several xeno-
estrogens has been described in GH3/B6 pitu-
itary tumor cells (Bulayeva and Watson 2004).
Recently, BPA and other xenoestrogens have
been shown to mediate Ca2+ inﬂux and pro-
lactin release in GH3/B6 pituitary tumor cells
at low concentrations (Wozniak et al. 2005).
Evidence shows that BPA activates NO synthe-
sis in endothelial cells (Noguchi et al. 2002),
the release of dopamine in PC12 cells (Yoneda
et al. 2003), caspase-3 in neurons (Negishi
et al. 2003), and ERKs and protein kinase C in
immune system cells (Canesi et al. 2004).
Because all of these actions are blocked by the
pure antiestrogen ICI182,780, a classical ER
should be involved.
Other actions triggered by endocrine dis-
ruptors are not blocked by ICI182,780, and
they probably do not involve classical ERs.
These include rapid effects of environmental
pollutants, such as 4-octylphenol, nonyl-
phenol, and o,p´-DDT, that inhibit Ca2+
channels in smooth muscle cells (Ruehlmann
et al. 1998); the activation of the nuclear fac-
tor of activated T-cell (NF-AT) signaling
pathways (Lee et al. 2004); and the activation
of AP-1–mediated gene expression in cells
that do not express classic ERs (Frigo et al.
2002). In human breast cancer cells, BPA
modifies Ca2+ signals in a rapid manner
(Walsh et al. 2005). In pancreatic β-cells, low
concentrations of BPA activate the transcrip-
tion factor CREB via a calcium-dependent
mechanism that is activated by an ncmER
(Quesada et al. 2002). CREB phosphoryla-
tion activated by BPA will bind to CRE
(cAMP-responsive element) and in turn mod-
ulate DNA transcription. This suggests that
the activation of steroid membrane receptors
can produce cellular effects through genomic
mechanisms.
There is a current debate regarding the
concentration of EDCs needed to produce
biologic effects in both humans and animals
(Kaiser 2000; Welshons et al. 2003), especially
because BPA is highly unstable in water and
undergoes biodegradation to a less active com-
pound (Staples et al. 1998; Zalko et al. 2003).
This would account for the BPA half-life of 2
days estimated in rivers (Zalko et al. 2003).
Despite this, drinking water still has traces of
BPA (Takahashi and Oishi 2000), which have
cellular effects (Hunt et al. 2003; Quesada
et al. 2002; Welshons et al. 2003). In the
endocrine pancreas, only nanomolar concen-
trations of BPA are required to modify the
physiology of α- and β-cells. Furthermore,
low concentrations of EDCs are enough not
only to produce nongenomic effects but also
to affect genomic pathways (Frigo et al. 2002;
Quesada et al. 2002).
Ca2+ signals control many cellular
processes, including secretion and gene expres-
sion. In pancreatic α-cells, glucagon release is
Ca2+ dependent. In the absence of glucose,
α-cells present an oscillatory [Ca2+]i pattern
that triggers glucagon secretion; this pattern is
suppressed as the concentration of glucose is
increased (Nadal et al. 1999), and a dimin-
ished glucagon secretion can be expected
(Johansson et al. 1987). Unlike β-cells, α-cells
are not synchronized (Nadal et al. 1999).
Therefore, α-cells are subject to their individ-
ual sensitvity to stimuli, including low glucose.
This may explain the heterogeneity in
response to 17β-E2 and environmental estro-
gens. Like for low glucose, some α-cells
respond to estrogen and xenoestrogens with
complete blockade of calcium oscillations,
whereas other cells only decrease the frequency
of such oscillations (Nadal et al. 1999). The
reason may be different levels of ncmER or
any of the steps along the signaling pathway
responsible for this effect. The effect of BPA
and DES we observed is similar to the one
produced by glucose, the suppression of the
[Ca2+]i movements that, in turn, decrease
glucagon release (Nadal et al. 1999).
A disruption of glucose signaling process in
α-cells by endocrine disruptors may have
important implications for normal physiology.
Glucagon acts via a seven-transmembrane
domain GPCR (Jelinek et al. 1993), which has
been identified in multiple tissues including
liver, brain, kidney, intestine, adipose tissue,
and pancreas (Christophe 1996; Jiang and
Zhang 2003). The main physiologic role of
glucagon is to stimulate the hepatic glucose
output, increasing glycemia. This provides the
major counter-regulatory mechanism for
insulin by maintaining the glucose homeostasis
in blood. It also has an important effect in
inducing lipolysis and the release of fatty acids
from adipose tissue when blood glucose is low.
In the present study, E2, BPA, and DES all
decrease α-cell signaling when glucose is low.
This effect should diminish glucogenolysis as
well as lipolysis and fatty acid release from
adipocytes, contributing to a higher adiposity.
Therefore, the signaling pathway under-
lying the effects of EDCs described in this
study reinforces the existence of a new sce-
nario that explains some of the low-dose
effects of EDCs: an action through new bind-
ing sites that rapidly activate different signal-
ing cascades outside the cell nucleus.
Furthermore, it describes the possibility that
low doses of EDCs affect the normal physiol-
ogy of the endocrine pancreas, altering the
regulation of glucose and lipid metabolisms.
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